The FDA has approved the first treatment for a rare form of Batten disease in which initial symptoms including language delay, epilepsy, and ataxia affect young children, usually at age 2 to 4 years.
Cerliponase alfa, marketed as Brineura, was approved to slow ambulation loss in symptomatic children aged 3 years or older who have late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidal peptidase-1 (TPP1) deficiency. Neuronal ceroid lipofuscinoses are rare, inherited neurodegenerative disorders known collectively as Batten disease.
Voelker R. Therapy for Rare Nerve Cell Disease. JAMA. 2017;317(21):2157. doi:10.1001/jama.2017.6334
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: